加科思：Pan-KRAS抑制剂AB-23E73新药临床实验申请获批

每日经济新闻09-26

每经AI快讯，加科思公告，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请已经获得国家药品监督管理局药品审评中心批准。此前，美国的IND申请也已获得美国食品药品监督管理局批准，将在中国和美国同步开展I/IIa期晚期实体瘤临床试验。（文章来源：每日经济新闻）

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2470220990?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-26 12:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470220990","market":"hk","top_or_hot":-1,"title":"加科思：Pan-KRAS抑制剂AB-23E73新药临床实验申请获批","media":"每日经济新闻","content":"<div>\n<p>每经AI快讯，加科思公告，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请已经获得国家药品监督管理局药品审评中心批准。此前，美国的IND申请也已获得美国食品药品监督管理局批准，将在中国和美国同步开展I/IIa期晚期实体瘤临床试验。（文章来源：每日经济新闻）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202409263191768852.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>加科思：Pan-KRAS抑制剂AB-23E73新药临床实验申请获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n加科思：Pan-KRAS抑制剂AB-23E73新药临床实验申请获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-26 12:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202409263191768852.html><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经AI快讯，加科思公告，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请已经获得国家药品监督管理局药品审评中心批准。此前，美国的IND申请也已获得美国食品药品监督管理局批准，将在中国和美国同步开展I/IIa期晚期实体瘤临床试验。（文章来源：每日经济新闻）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202409263191768852.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0029874061.USD","symbol_name":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202409263191768852.html","article_id":"2470220990","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202409263191768852.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2470220990","pubTimestamp":1727325383,"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"每经AI快讯，加科思公告，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请已经获得国家药品监督管理局药品审评中心批准。此前，美国的IND申请也已获得美国食品药品监督管理局批准，将在中国和美国同步开展I/IIa期晚期实体瘤临床试验。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","AB":"联博控股","BK4590":"PTP","BK4135":"资产管理与托管银行"},"translate_title":"Garcos: Pan-KRAS inhibitor AB-23E73 new drug clinical trial application approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AB":1},"content_text":"每经AI快讯，加科思公告，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请已经获得国家药品监督管理局药品审评中心批准。此前，美国的IND申请也已获得美国食品药品监督管理局批准，将在中国和美国同步开展I/IIa期晚期实体瘤临床试验。（文章来源：每日经济新闻）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470220990"}